甲状腺癌患者体内Th9在相关肿瘤微环境作用下抗肿瘤机制分析及对预后的影响研究  

Analysis of the anti-tumor mechanism of Th9 in thyroid cancer patients under the influence of relevant tumor microenvironment and its impact on prognosis

作　　者：吴腊梅 杨慧健 何雁鸿 董成林 黄琳欢 WU Lamei;YANG Huijian;HE Yanhong;DONG Chenglin;HUANG Linhuan(Department of Clinical Laboratory,Anting Hospital of Jiading District,Shanghai 201800,China;Department of Clinical Laboratory,Shanghai Zhongye Hospital,Shanghai 200941,China)

机构地区：[1]上海市嘉定区安亭医院检验科,上海201800 [2]上海中冶医院检验科,上海200941

出　　处：《国际检验医学杂志》2024年第S02期60-64,共5页International Journal of Laboratory Medicine

基　　金：上海市卫生和健康委员会青年基金(20184Y0087),上海市嘉定区自然科学基金(JDKW-2021-0052),上海中冶医院科研孵化项目(23-ZYKYA-07)。

摘　　要：目的探讨甲状腺癌患者体内Th9在相关肿瘤微环境作用下抗肿瘤机制分析及对预后的影响。方法选择2018年3月至2020年3月甲状腺癌患者80例设为观察组;选择同期健康体检者80例设为对照组,并常规收集两组甲状腺标本。(1)血液指标测定。分别于术前、手术7 d后采集两组血液标本(乳头状癌40例、甲状腺髓样癌40例)。血清分离后采用酶联免疫吸附试验测定血液生化指标;采用定量PCR法测定白细胞介素(IL)-1β、IRT-1、PU.1、SMAD2、转化生长因子(TGF)-β、STAT3等指标;采用流式细胞仪测定两组Th及ILC-2细胞中IL-9水平;(2)标本采集。术后采集甲状腺癌病灶及癌旁标本,采用定量PCR法测定病灶组织及癌旁组织中IL-25、IL-33、IL-1β、IL-13、RORα及IL-9表达水平。结果观察组甲状腺癌患者术前IL-10、IL-4、IL-33、IL-25、IL-1β、IL-9、IL-21水平高于对照组(P<0.05);观察组手术7 d后IL-10、IL-4、IL-33、IL-25、IL-1β、IL-9、IL-21水平低于手术前(P<0.05);观察组IL-1β、IRT-1、PU.1、SMAD2、TGF-β、STAT3 mRNA水平高于对照组(P<0.05);流式细胞仪测定结果表明:观察组Th(CD3^(+)IL-4+IL-9+)及ILC-2细胞IL-9阳性率高于对照组(P<0.05);甲状腺癌患者病灶组织中IL-25、IL-33、IL-1β、IL-13、RORα及IL-9 mRNA水平高于癌旁组织(P<0.05)。结论甲状腺癌患者体内Th9在相关肿瘤微环境中能发挥重要的调节作用,能提高抗肿瘤作用,有助于改善患者预后,有望成为甲状腺癌患者治疗新靶点。Objective To investigate the anti-tumor mechanism of Th9 in thyroid cancer patients under the action of related tumor microenvironment and its impact on prognosis.Methods From March 2018 to March 2020,a total of 80 patients with thyroid cancer were selected as the observation group.80 healthy people who underwent physical examination during the same period were selected as the control group,and thyroid sam-ples were routinely collected from both groups.(1)Determination of blood indexes.Two groups of blood sam-ples(40 cases of papillary carcinoma and 40 cases of medullary thyroid carcinoma)were collected before oper-ation and 7 days after operation.After serum separation,enzyme-linked immunosorbent assay was used to de-termine blood biochemical indicators.Quantitative PCR was used to determine interleukin-1(IL)-1β,IRT-1,PU.1,SMAD2,transforming growth factor(TGF)-β,STAT3 and other indicators.Flow cytometry was used to determine Th and IL-9 levels in ILC-2 cells.(2)Specimen collection.Thyroid cancer lesions and paracancer-ous specimens were collected after operation,and quantitative PCR was used to determine the expression lev-els of IL-25,IL-33,IL-1β,IL-13,RORαand IL-9 in lesion tissue and paracancerous tissue.Results The preop-erative levels of IL-10,IL-4,IL-33,IL-25,IL-1β,IL-9 and IL-21 in patients with thyroid cancer in the observa-tion group were higher than those in the control group(P<0.05).After 7 days,the levels of IL-10,IL-4,IL-33,IL-25,IL-1β,IL-9 and IL-21 were lower than those before surgery(P<0.05).The mRNA levels of PU.1,SMAD2,TGF-βand STAT3 were higher than those in the control group(P<0.05).The results of flow cy-tometry showed that the positive rates of IL-9 in Th((CD3^(+)IL-4+IL-9+))and ILC-2 cells in the observation group were higher than those in the control group(P<0.05).The mRNA levels of IL-25,IL-33,IL-1β,IL-13,RORαand IL-9 in the lesion tissue of patients with thyroid cancer were higher than those in the adjacent tissue(P<0.05).Conclusion Th9 in patients with thyroid cancer could pla

关 键 词：甲状腺癌 肿瘤微环境 抗肿瘤机制 治疗新靶点 流式细胞仪 定量PCR法 

分 类 号：R736.1[医药卫生—肿瘤]